IRLAB Therapeutics AB (IRLAB A):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:IRLAB Therapeutics AB (IRLAB A) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8220
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:44
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スウェーデン
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
IRLAB Therapeutics AB (IRL) is a pharmaceutical company that discovers and develops drugs to treat central nervous system associated diseases. The company conducts flagship technology integrative screening process, a phenotypic screening and systems pharmacology process is used for development its therapeutic products. Its products comprise IRL790 for treating parkinson disease psychosis and L-dopa induced dyskinesias in parkinson’s disease, IRL752 for treatment of dementia, IRL626 for treating schizophrenia, P001 for treating attention disorders, and IRL448 and IRL555. It offers development of drugs to assist patients with Parkinson’s disease. IRL is headquartered in Gothenburg, Sweden.

IRLAB Therapeutics AB (IRLAB A) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
IRLAB Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
IRLAB Therapeutics AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
IRLAB Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
IRLAB Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
IRLAB Therapeutics AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
IRLAB Therapeutics AB, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
IRLAB Therapeutics Raises USD3.5 Million in Venture Financing 10
Partnerships 11
IRLAB Therapeutics Enters into Agreement with Clinical Trial 11
Equity Offering 12
IRLAB Therapeutics Raises USD16 Million in Private Placement of Shares 12
IRLAB Therapeutics Raises USD12.9 Million in IPO 14
IRLAB Therapeutics Raises USD13 Million in Rights Offering of Shares 15
IRLAB Therapeutics AB – Key Competitors 16
IRLAB Therapeutics AB – Key Employees 17
IRLAB Therapeutics AB – Locations And Subsidiaries 18
Head Office 18
Recent Developments 19
Financial Announcements 19
Aug 29, 2017: IRLAB Interim Report April-June 2017 19
May 16, 2017: IRLAB Therapeutics Interim Report January-March 2017 21
Feb 27, 2017: IRLAB Therapeutics Year-end report for 2016 23
Corporate Communications 26
Sep 20, 2017: Nomination committee appointed in IRLAB 26
Jun 30, 2017: IRLAB appoints new CFO and recruits researchers 27
Apr 24, 2017: Nomination Committee’s proposal for a Board of Directors of IRLAB Therapeutics 28
Product News 29
Sep 19, 2018: IRLAB nominates two new candidate drugs and updates the pipeline 29
Clinical Trials 31
Aug 30, 2018: IRLAB reports promising efficacy data from Phase IIa-study with IRL752 31
Jun 29, 2018: IRLAB reports top-line results from Phase IIa study with IRL752 32
Jan 31, 2018: IRLAB Provides Update On Clinical Phase II pipeline – IRL752 33
Jan 31, 2018: IRLAB Provides Update On Clinical Phase II pipeline – IRL790 35
Nov 15, 2017: IRLAB receives MHRA approval to conduct Phase II trials with IRL790 in Britain 37
Oct 05, 2017: IRLAB receives approval from the Finnish MPA (Fimea) 38
Oct 04, 2017: IRLAB starts Phase II study with IRL752 for the treatment of Parkinson’s disease dementia 39
Aug 25, 2017: IRLAB receives approval to initiate Phase II trials with IRL752 40
May 24, 2017: IRLAB patent application for large-scale production method 41
May 15, 2017: IRLAB announces positive results from study with IRL790 42
Mar 16, 2017: IRLAB Therapeutics reports positive results from clinical phase 1 studies for IRL752 and includes agreements to conduct Phase 2 studies 43
Appendix 44
Methodology 44
About GlobalData 44
Contact Us 44
Disclaimer 44

List of Tables
IRLAB Therapeutics AB, Pharmaceuticals & Healthcare, Key Facts, 2017 2
IRLAB Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
IRLAB Therapeutics AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
IRLAB Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
IRLAB Therapeutics AB, Deals By Therapy Area, 2012 to YTD 2018 8
IRLAB Therapeutics AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
IRLAB Therapeutics Raises USD3.5 Million in Venture Financing 10
IRLAB Therapeutics Enters into Agreement with Clinical Trial 11
IRLAB Therapeutics Raises USD16 Million in Private Placement of Shares 12
IRLAB Therapeutics Raises USD12.9 Million in IPO 14
IRLAB Therapeutics Raises USD13 Million in Rights Offering of Shares 15
IRLAB Therapeutics AB, Key Competitors 16
IRLAB Therapeutics AB, Key Employees 17

List of Figures
IRLAB Therapeutics AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
IRLAB Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
IRLAB Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
IRLAB Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
IRLAB Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
IRLAB Therapeutics AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
IRLAB Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
IRLAB Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[IRLAB Therapeutics AB (IRLAB A):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • China Aerospace Science and Technology Corporation:企業の戦略・SWOT・財務情報
    China Aerospace Science and Technology Corporation - Strategy, SWOT and Corporate Finance Report Summary China Aerospace Science and Technology Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's struct …
  • Sanofi-Aventis Korea Co Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Sanofi-Aventis Korea Co Ltd (Sanofi-Aventis), a subsidiary of Sanofi is a developer, manufacturer and distributor of generic drugs and medical equipment. The company’s products include note vials lantus, lantus state solo star, she feeds the main vial la, feed her a solo star la shares, elro …
  • Ferrellgas Partners LP (FGP):企業の財務・戦略的SWOT分析
    Summary Ferrellgas Partners LP (Ferrellgas) is an oil and gas company that supplies propane and related equipment. The company provides transportation, wholesale marketing, and distribution of propane. It also carries out selling refined fuels and feedstocks. Ferrellgas provides propane crop drying, …
  • Esprit Holdings Limited:企業の戦略・SWOT・財務分析
    Esprit Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Esprit Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Eveon SAS:製品パイプライン分析
    Summary Eveon SAS (Eveon) engages in the designing, development and manufacturing the automated medical devices for the preparation and administration of complex drugs. The company also manufactures the customized products for the Pharma industry that develops from prototyping. It offers solutions t …
  • Brown-Forman Corporation:戦略・SWOT・企業財務分析
    Brown-Forman Corporation - Strategy, SWOT and Corporate Finance Report Summary Brown-Forman Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Beach Energy Ltd (BPT):石油・ガス:M&Aディール及び事業提携情報
    Summary Beach Energy Ltd (Beach Energy) is an independent upstream oil and gas company. It carries out the exploration, development, production, transportation and marketing of oil and natural gas. The company has core exploration and development drilling operations in the Cooper and Eromanga basins …
  • Aurora Energy Pty Ltd:企業の戦略・SWOT・財務分析
    Aurora Energy Pty Ltd - Strategy, SWOT and Corporate Finance Report Summary Aurora Energy Pty Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Heidrick & Struggles International Inc (HSII):企業の財務・戦略的SWOT分析
    Summary Heidrick & Struggles International Inc (Heidrick & Struggles) is a provider of business advisory and consulting services. The company’s services comprise executive search, leadership consulting, and culture shaping services. Its leadership consulting services include leadership assessment an …
  • Brady Corporation (BRC):企業の財務・戦略的SWOT分析
    Brady Corporation (BRC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • ORBCOMM Inc (ORBC):企業の財務・戦略的SWOT分析
    ORBCOMM Inc (ORBC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • CTS Corp (CTS):企業の財務・戦略的SWOT分析
    Summary CTS Corp (CTS) is a manufacturer of actuators, sensors and electronic components. The company offers products such as controls, pedals, piezoelectric sense products, sensors, switches, transducers, RFI filters, frequency control products, RF filters, specialty capacitors, specialty resistors …
  • Digimarc Corp (DMRC):企業の財務・戦略的SWOT分析
    Summary Digimarc Corp (Digimarc) is a technology company that offers develops solutions, license intellectual property and provides development services to businesses and government. The company offers products such as digimarc discover, online image safeguards and digimarc guardian. Digimarc’s Disc …
  • Mission Therapeutics Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Mission Therapeutics Ltd (Mission) is a provider of deubiquitylating enzyme drug discovery and development programs. The company develops USP30, USP10 and UHCL1 for patients with mitochondria diseases, neurodegeneration, inflammation and others. the company uses its proprietaryDUB platform t …
  • algoWatt SpA (ALW):企業の財務・戦略的SWOT分析
    Summary algoWatt SpA (algoWatt), formerly TerniEnergia SpA, is an energy services provider. It designs, develops and integrates solutions for the management of energy and natural resources. The company’s product offerings include building energy management systems, control and maintenance systems, e …
  • Top Image Systems Ltd. (TISA):企業の財務・戦略的SWOT分析
    Top Image Systems Ltd. (TISA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Capitec Bank Holdings Limited (CPI):企業の財務・戦略的SWOT分析
    Capitec Bank Holdings Limited (CPI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Aradigm Corp (ARDM):企業の財務・戦略的SWOT分析
    Aradigm Corp (ARDM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • National Industrialization Co (2060):企業の財務・戦略的SWOT分析
    National Industrialization Co (2060) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Immuno-Biological Laboratories Co Ltd (4570):製薬・医療:M&Aディール及び事業提携情報
    Summary Immuno-Biological Laboratories Co Ltd (IBL) is a pharmaceutical company that develops, manufactures and markets diagnostic products. The company provides business areas such as diagnostic and research reagents, customized services, global sales network, protein production business using tran …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆